TLDR
- Shares of Moderna rose up to 9.1% following positive FDA briefing documents that identified no “major deficiencies” in the mFlusiva mRNA flu vaccine application
- The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene June 18 to determine whether mFlusiva’s benefits justify its risks for individuals 50 years and above
- mFlusiva could become America’s inaugural mRNA-based seasonal influenza vaccine if approved, with the FDA’s final ruling anticipated by August 5
- The biotech firm is pursuing standard approval for the 50-64 age bracket and expedited approval for those 65 and older
- Concurrent with the regulatory news, Moderna revealed an organizational overhaul, appointing Ester Banque to lead commercial operations in preparation for potential launches between 2027-2028
Shares of Moderna (MRNA) surged by as much as 9.1% during Tuesday’s trading session following the publication of FDA staff briefing materials that suggested data supporting mFlusiva’s effectiveness in adults aged 65 and above. The biotechnology company’s stock reached approximately $56.12, hovering near its 52-week peak of $57.80.
These briefing materials arrived ahead of Thursday’s scheduled Vaccines and Related Biological Products Advisory Committee (VRBPAC) session, during which panel members will determine whether mFlusiva’s advantages outweigh potential risks for adults in the 50-plus age category.
Significantly, FDA staff reviewers identified no “major deficiencies” within the submission. This favorable assessment represented exactly the validation market participants had been anticipating.
The regulatory journey hasn’t been without obstacles. Last February, the FDA delivered a “refuse-to-file” notification, expressing reservations about trial methodology—particularly that participants aged 65 and older in the control group received standard-dose influenza vaccines instead of the high-dose formulation recommended by the CDC for seniors. However, the agency reversed its position within days after Moderna committed to modifying its submission.
That regulatory uncertainty created market volatility. Tuesday’s briefing documents signaled a notably more positive stance.
Jefferies analyst Andrew Tsai characterized the evaluation as encouraging, forecasting combined U.S. revenue of $750 million from flu and COVID-flu combination vaccines by 2030.
FDA Staff Assessment Details
According to FDA reviewers, mFlusiva demonstrated enhanced relative vaccine efficacy compared to standard-dose flu vaccines in individuals aged 50 through 64. For the senior population aged 65 and above, the submission relies primarily on immunogenicity evidence rather than direct efficacy comparisons against high-dose alternatives.
Reviewers acknowledged certain constraints. The vaccine’s performance has been evaluated across only a single flu season, and trial protocols excluded immunocompromised individuals and particularly frail elderly participants, creating uncertainty regarding effectiveness in these vulnerable populations.
Moderna has committed to conducting supplementary research and providing additional evidence for the 65-plus demographic if accelerated approval is granted for that age segment.
The pharmaceutical company seeks conventional approval for adults between 50 and 64 while requesting accelerated approval for the 65-and-older population. The FDA’s conclusive determination is scheduled for August 5.
Upon approval, mFlusiva would represent the United States’ first messenger RNA-based seasonal influenza vaccine.
Leadership Changes Position Moderna for Product Pipeline Expansion
Coinciding with the regulatory developments, Moderna unveiled a strategic reorganization. The company named Ester Banque as Chief Commercial Officer, positioning the organization for approximately three anticipated product introductions—including a combination flu/COVID vaccine and a norovirus vaccine—projected for rollout during 2027 and 2028.
The combination of improved regulatory clarity and a defined commercial strategy provided sufficient momentum to drive share prices upward.
Moderna has gained 81.8% year-to-date. Nevertheless, despite this impressive rally, investors who allocated $1,000 to MRNA five years ago would currently hold assets worth merely $283.65.
The VRBPAC advisory vote is scheduled for June 18.
